Discrepant MR and [(18)F]Fluoroethyl-L-Tyrosine PET Imaging Findings in a Patient with Bevacizumab Failure

Antiangiogenic treatment using bevacizumab may cause difficulties in distinguishing between antivascular and true antitumor effects when using MRI response criteria based on changes of contrast enhancement (i.e., Macdonald criteria). Furthermore, more precise tumor response assessment criteria (i.e....

Descripción completa

Detalles Bibliográficos
Autores principales: Galldiks, Norbert, Filss, Christian P., Goldbrunner, Roland, Langen, Karl-Josef
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2012
Materias:
Published online: September, 2012
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3529567/
https://www.ncbi.nlm.nih.gov/pubmed/23271997
http://dx.doi.org/10.1159/000342480

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3529567/
https://www.ncbi.nlm.nih.gov/pubmed/23271997
http://dx.doi.org/10.1159/000342480

Ejemplares similares